Genprex, Inc. (GNPX) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Genprex reported revenue of $0. Net income was -$16.2M. Operating activities generated -$15.3M of cash. At fiscal year end, Genprex held $10.2M in total assets against $2.2M in total liabilities, including $7.8M of cash and equivalents.
Open the full interactive Genprex financials → Quarterly statements, key ratios, valuation history and price charts.
Genprex Key Stats
| Share Price | $2.51 |
|---|---|
| Market Cap | $1.2M |
| 52-Week Range | $2.51 – $924.00 |
| Shares Outstanding | 473,162 (basic, 2026 Q2) |
Genprex Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | — | $0 | $0 | $0 | $0 | $0 |
| Cost of Goods Sold | $18.0M | $19.6M | $23.8M | $31.1M | $21.2M | — |
| Gross Profit | -$18.0M | -$19.6M | -$23.8M | -$31.1M | -$21.2M | — |
| Operating Income | -$18.0M | -$19.6M | -$23.8M | -$31.1M | -$21.2M | -$15.5M |
| Pre-Tax Income | -$17.9M | -$19.6M | -$23.7M | -$30.9M | -$21.1M | -$16.2M |
| Income Tax | — | — | — | $0 | $2,650 | $0 |
| Net Income | -$17.9M | -$19.6M | -$23.7M | -$30.9M | -$21.1M | -$16.2M |
| Diluted EPS | -$22440.00 | -$18480.00 | — | — | — | — |
Genprex Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$3.8M | -$3.8M | -$4.5M | -$4.4M |
Genprex Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | — | — | — | $6.7M | $1.6M | $7.8M |
| Current Assets | $30.7M | $39.1M | $21.5M | $7.5M | $2.1M | $8.4M |
| Total Assets | $31.4M | $42.9M | $25.1M | $10.7M | $4.1M | $10.2M |
| Current Liabilities | $450,724 | $1.6M | $2.8M | $3.3M | $2.5M | $2.2M |
| Total Liabilities | $450,724 | $1.6M | $2.8M | $3.3M | $2.5M | $2.2M |
| Shareholders' Equity | $30.9M | $41.3M | $22.3M | $7.4M | $1.6M | $8.0M |
Genprex Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$13.9M | -$14.3M | -$17.8M | -$24.7M | -$17.1M | -$15.3M |
| Cash From Investing | -$2.3M | -$83,796 | $97,731 | -$71,214 | $1,166 | $0 |
| Cash From Financing | $41.6M | $25.7M | $6,426 | $10.6M | $12.0M | $21.5M |
| Free Cash Flow | -$14.0M | -$14.3M | -$17.8M | — | — | — |
Figures from Genprex's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Genprex financials page for every line item.
Genprex Company Profile
| Ticker | GNPX |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Austin, Texas |
| Incorporated in | Texas |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001595248 |
Frequently Asked Questions
What was Genprex's revenue in fiscal 2025?
Genprex (GNPX) reported revenue of $0 for fiscal 2025.
What is Genprex's annual revenue history?
Genprex's annual revenue by fiscal year: 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was Genprex's net income in fiscal 2025?
Genprex reported net income of -$16.2M for fiscal 2025.
What was Genprex's revenue last quarter?
In its most recent reported quarter (2026 Q2), Genprex reported revenue of $0.
How many shares of Genprex are outstanding?
Genprex reported a weighted average of 473,162 basic shares outstanding in 2026 Q2.
What is Genprex's market cap?
Based on its latest closing price, Genprex (GNPX) has a market capitalization of about $1.2M.
When does Genprex's fiscal year end?
Genprex's fiscal year end, as registered with the SEC, is December 31.
Where is Genprex headquartered?
Genprex lists its business address in Austin, Texas in its SEC filings.